RxDoctor Payments DataLook up a doctor →

Roel Querubin, MD

Rheumatology · Marietta, GANPI 1124154323

Payments from drug & device makers

$1,520,106in general payments, 2019–2025

Across 1,604 payments — averaging $947.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$328K
  • Eli Lilly$286K
  • AbbVie$239K
  • E.r. Squibb & Sons, L.L.C.$169K
  • GSK$169K
  • Pfizer$136K
  • plus $195K from 41 others
$131in research payments, 2019–2025

Across 2 payments — averaging $65.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$131

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,520,106 in reported general payments places this provider in the 95th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$673,371
Medicare patients
164
Services billed
43,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →